On Thursday, Nielsen Holdings PLC (NYSE:NLSN)’s shares declined -0.13% to $47.18.
Nielsen released Increasingly Affluent, Educated and Diverse: African-American Consumers - the Untold Story, the fifth installment in its Diverse Intelligence Series. This new report is inclusive of insights about affluent Black consumers with annual household incomes of $75,000 and higher and upends outdated stereotypes about African-Americans, from education and income to media consumption and social engagement. The report was released at a press conference during the Congressional Black Caucus Foundation, Inc.’s 45th Annual Legislative Conference in Washington, D.C.
Increasingly Affluent, Educated and Diverse: African-American Consumers - the Untold Story explores the evolution of upper-income Black Americans as the population continues to grow and change rapidly. At 45.7 million strong [1], the nation’s Black population grew at 17.7% from 2000 to 2014 — 35% faster than the total population and double the 8.2% growth rate of the White population. The growth rate of the Black population is partly attributed to the surge in Black immigration from the Caribbean, Africa and some European countries, making the overall population incredibly diverse. The number of foreign-born Blacks in the U.S. has quadrupled since 1980, accounting for 3.8 million of the nation’s Black population. Foreign-born Blacks are contributing to raised incomes in the African-American community: their median household incomes are 30% higher than U.S.-born Blacks.
Nielsen Holdings plc operates as an information and measurement company. The company provides media and marketing information, analytics, and manufacturer and retailer expertise about what and where consumers buy, read, watch, and listen. Its Buy segment provides data on retail measurement services, such as market share and competitive sales volumes; insights into distribution, pricing, merchandising, and promotion; consumer panel measurement, which offers insight into shopper behavior and customer segmentation; and consumer intelligence and analytical services for decision making in development and marketing cycles.
Array Biopharma Inc(NASDAQ:ARRY)’s shares gained 2.96% to $5.91.
Array BioPharma Inc. (ARRY) declared presentations on encorafenib and binimetinib at the 2015 European Cancer Congress (ECC), which will be held September 25 - 29, 2015 in Vienna, Austria. These products are presently advancing in a total of three pivotal trials, with top-line results predictable over the next year from the NEMO (binimetinib monotherapy in NRAS mutant melanoma) and COLUMBUS (binimetinib and encorafenib in BRAF mutant melanoma) Phase 3 trials.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
At the end of Thursday’s trade, Seattle Genetics, Inc. (NASDAQ:SGEN)‘s shares surged 1.50% to $48.68.
Seattle Genetics, Inc. (SGEN) announced the pricing of an underwritten public offering of 11,707,318 shares of its common stock at a price to the public of $41.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $480 million. The offering was upsized by 20 percent from the originally anticipated gross offering amount of $400 million. The offering is expected to close on or about September 16, 2015, subject to customary closing conditions. In addition, Seattle Genetics has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,756,097 shares of its common stock at the public offering price, less the underwriting discounts and commissions, solely to cover overallotments.
Seattle Genetics anticipates using the net proceeds from the offering to fund the ongoing commercialization of ADCETRIS® (brentuximab vedotin) in the United States and Canada, to fund its research and development efforts designed to further expand the ADCETRIS label and to advance its pipeline of product candidates, in addition to for general corporate purposes, counting working capital.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially accessible in about 55 countries, counting the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in partnershipwith Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in about 30 ongoing clinical trials, counting Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, in addition to in Phase I and II studies in various lymphoma and non-lymphoma indications.
Lazard Ltd(NYSE:LAZ), ended its Thursday’s trading session with 3.20% gain, and closed at $48.76.
The Board of Directors of Lazard Global Total Return and Income Fund, Inc. (the “Fund”) (LGI) has authorized the Fund to declare, following a level distribution policy, a monthly distribution of $0.09282 per share on the Fund’s outstanding common stock. The distribution is payable on October 23, 2015 to shareholders of record on October 9, 2015. The ex-dividend date is October 7, 2015.
Lazard Ltd., together with its auxiliaries, operates as a financial advisory and asset administration firm. Its Financial Advisory segment offers various financial advisory services on mergers and acquisitions, and other planned matters, in addition to on restructurings, capital structure, capital raising, and other financial matters. Th
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
